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Abstract 
The recent advancement of nanotechnology has provided unprecedented opportunities for the 
development of nanoparticle enabled technologies for detecting and treating cancer. Here, we 
reported the construction of a PET trackable organic nanoplatform based on phage particle for 
targeted tumor imaging. Method: The integrin αvβ3 targeted phage nanoparticle was constructed 
by expressing RGD peptides on its surface. The target binding affinity of this engineered phage 
particle  was  evaluated  in  vitro.  A  bifunctional  chelator  (BFC)  1,4,7,10-tetraazadodecane- 
N,N',N",N"'-tetraacetic acid (DOTA) or 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo [6.6.6] ico-
sane-1-ylamino) methyl) benzoic acid (AmBaSar) was then conjugated to the phage surface for 
64Cu
2+ chelation. After 
64Cu radiolabeling, microPET imaging was performed in U87MG tumor 
model  and  the  receptor  specificity  was  confirmed  by  blocking  experiments.  Results:  The 
phage-RGD demonstrated target specificity based on ELISA experiment. According to the TEM 
images, the morphology of the phage was unchanged after the modification with BFCs. The labeling 
yield was 25 ± 4% for 
64Cu-DOTA-phage-RGD and 46 ± 5% for 
64Cu-AmBaSar-phage-RGD, re-
spectively.  At  1  h  time  point, 
64Cu-DOTA-phage-RGD  and 
64Cu-AmBaSar-phage-RGD  have 
comparable tumor uptake (~ 8%ID/g). However, 
64Cu-AmBaSar-phage-RGD showed significantly 
higher  tumor  uptake  (13.2  ±  1.5  %ID/g,  P<0.05)  at  late  time  points  compared  with 
64Cu-DOTA-phage-RGD (10 ± 1.2 %ID/g). 
64Cu-AmBaSar-phage-RGD also demonstrated signif-
icantly lower liver uptake, which could be attributed to the stability difference between these 
chelators. There is no significant difference between two tracers regarding the uptake in kidney 
and muscle at all time points tested. In order to confirm the receptor specificity, blocking ex-
periment was performed. In the RGD blocking experiment, the cold RGD peptide was injected 2 
min before the administration of 
64Cu-AmBaSar-phage-RGD. Tumor uptake was partially blocked 
at 1 h time point. Phage-RGD particle was also used as the competitive ligand. In this case, the 
tumor uptake was significantly reduced and the value was kept at low level consistently. Con-
clusion: In this report, we constructed a PET trackable nanoplatform based on phage particle and 
demonstrated the imaging capability of these targeted agents. We also demonstrated that the 
choice of chelator could have significant impact on imaging results of nano-agents. The method 
established in this research may be applicable to other receptor/ligand systems for theranostic 
agent construction, which could have an immediate and profound impact on the field of imag-
ing/therapy  and  lay  the  foundation  for  the  construction  of  next  generation  cancer  specific 
theranostic agents. 
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INTRODUCTION 
During the last decade, tremendous progress has 
been  made  in  the  development  of  new  molecular 
imaging  probes  and  therapeutic  agents  targeting 
cancer  [1-4].  However,  cancer  still  remains  a  major 
fatal disease around the world. There is clearly a need 
to  develop  innovative  diagnostic  and  therapeutic 
methods beyond tradition and convention. Recently, 
the  advancement  of  nanotechnology  has  provided 
unprecedented opportunities for the development of 
nanoparticle  enabled  technologies  for  detecting  and 
treating  cancer  [5-8].  For  example,  surface 
functionalized  organic/inorganic  nanoparticles  hold 
the  great  promises  for  the  eradication  of  cancer  by 
creating  the  theranostic  systems  (therapy  + 
multifunctional  diagnosis)  that  enable  i)  early 
detection  of  the  disease,  ii)  monitoring  therapeutic 
response,  and  iii)  targeted  delivery  of  therapeutic 
agents, based on the “whole in one approach” [9, 10]. 
However, applications of these nanotechniques were 
limited by the potential toxicity from inorganic core 
and the lack of well controlled surface modification 
method [11, 12]. The development of well defined and 
biodegradable delivery systems is therefore preferred. 
As shown in Figure 1, phage particles are unique 
platforms for imaging probes or drug carriers in that 
1) they could be genetically modified to display target 
specific  ligands;  2)  they  can  be  economically  and 
effectively  produced  with  absolute  uniformity 
controlled  by  nature;  3)  they  can  be  covalently 
attached to radiometal chelators while simultaneously 
expressing  multiple  copies  of  cancer  targeting 
peptides;  4)  they  are  physically  well-characterized, 
resistant  to  harsh  conditions,  biocompatible  and 
nonpathogenic (compared with virus based particles); 
5)  the  genetic  material  inside  the  capsid  can  be 
removed without affecting the integrity of capsid [13]. 
Such empty container is ideal for encapsulating other 
therapeutic  reagents  which  can  be  released  after 
reaching specific cellular sites. These factors suggest 
that functionalized bacteriophage particles hold great 
potential  as  novel  advanced  imaging  agents  and 
targeting  systems  for  drug  and  DNA  delivery,  and 
will  likely  complement  existing  organic/inorganic 
nanoplatforms  [14-17].  Although  target  specific 
radiolabeled  phage  particles  obtained  from  either 
high  throughput  screen  (phage  display)  or  rational 
design (the expression of established affinity reagents 
on the phage surface) have been reported in molecular 
imaging of variety of diseases, most of the imaging 
results are still suboptimal [18, 19]. Both two-step and 
three-step pretargeted strategies have been explored 
for SPECT imaging  of cancer  [19, 20]. However, its 
application in theranostic approach is limited in some 
extend  due  to  the  complicated  procedures.  In  this 
report,  we  developed  a  set  of  phage  particle-based 
novel imaging agents with great therapeutic potential 
due  to  their  high  carrying  capacity  and  superior 
targeted delivery ability [21-23]. 
Positron  emission  tomography  (PET)  is  a 
non-invasive functional imaging technique with good 
resolution, high sensitivity, and accurate quantifica-
tion [24]. An important advantage of PET is  that it 
provides  quantitative  information  of  physiological, 
biochemical and pharmacological processes in living 
subjects.  The  vitronectin  receptor  integrin  αvβ3  has 
been  the  focus  of  intensive  research  because  of  its 
major role in  several distinct processes, particularly 
osteoclast  mediated  bone  resorption,  angiogenesis 
and pathological neovascularization, and tumor me-
tastasis [25, 26]. A variety of RGD peptide and anti-
body based probes have been reported for multimo-
dality  imaging  of  integrin  αvβ3  expression  in  vivo 
[27-30]. In our approach, we developed integrin αvβ3 
targeted phage particle for PET imaging.  
MATERIALS AND METHODS  
 All commercially available reagents were used 
without  further  purification.  DOTA  was  purchased 
from  Macrocyclics,  Inc.  AmBaSar  was  prepared  in 
house as reported in reference [31]. PD-10 column was 
purchased  from  GE  Healthcare. 
1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide 
(EDC),  N-hydroxysulfonosuccinimide  (SNHS),  and 
Chelex 100 resin (50 - 100 mesh) were purchased from 
Aldrich. Water and all buffers were passed through a 
Chelex 100 column (1 × 15 cm) before radiolabeling. 
64Cu  was  purchased  from  University  of 
Wisconsin-Madison or obtained from Shawn Chen’s 
group at NIBIB/NIH.  
Production of T7-RGD 
 To  construct  T7  bacteriophages  with 
RGD-containing  peptide  displayed  on  the  surface, 
two  primers,  5’-  aattctggcggcggcagctgcCGTGG 
TGATTTTAAAtgcTAA-3’  and  5’-  AGCTTTAgca 
TTTAAAATCACCACGgcagctgccgccgccag-3’  were 
synthesized,  self-annealed  and  inserted  into 
T7select415-1b  vector  previously  digested  by  EcoRI 
and Hind III following the instructions provided by 




Cloning  Kit,  Gibbstown,  NJ  08027)  .  The  ligated 
products were then subjected for in vitro packaging 
according to the protocol provided by manufacturer. 
The resulting recombinant phages were identified by 
PCR screen and named T7-RGD. The inserted DNA 
sequence was confirmed by DNA sequencing and led 
to  the  expression  of  the  following  peptide 
NSGGGSCRGDFKC where RGD sequence was con-
strained  by  two  cysteins  and  led  by  GGGS  flexible 
linker. 
Preparation of Cy5.5-Phage-RGD 
The preparation of Cy5.5 conjugated Phage-RGD 
was  achieved  using  a  water-soluble  procedure.  In 
brief, 1 mg of Cy5.5-NHS (1.5 μmol) was dissolved in 
100  μl  of  DMSO  and  saved  as  stock  solution.  The 
Cy5.5-NHS  and  Phage-RGD  was  added  at  1:5  ratio 
and the reaction mixture was incubated overnight at 
pH 8.5. The Cy5.5-Phage-RGD was purified by pass-
ing through a PD-10 column. The eluate was washed 
with  water  three  times  using  centricon  filter  (10K 
cut-off). The resulting solution was aliquoted for fu-
ture use.  
Chemistry and radiochemistry 
 DOTA and AmBaSar were activated and conju-
gated  to  the  phage  particle  using  a  water-soluble 
procedure reported earlier [32]. For example: 0.75 mg 
of AmBaSar (1.5 μmol) dissolved in 20 μL of water and 
0.29 mg of EDC (1.5 μmol) dissolved in 10 μL of water 
were mixed at pH 5.0. SNHS (0.26 mg, 1.2 μmol) in 10 
μL of water was then added to the stirring mixture on 
ice-bath, and the pH was adjusted to 5.5. The reaction 
was incubated for 30 min at 4 °C. The Phage-RGD was 
then added to the AmBaSar-OSSu reaction mixture at 
pH 8.5. The reaction was incubated at 4 °C for over-
night.  The  AmBaSar-Phage-RGD  was  purified  by 
passing  through  a  PD-10  column.  The  eluate  was 
washed with water three times using centricon filter. 




FIGURE  1.  (A)  Rationale  for  developing  PET  trackable  phage  nanoparticles.  (B)  The  synthetic  scheme  of 
DOTA-/AmBaSar-T7-RGD.  




The  64Cu-DOTA-Phage-RGD or  64Cu-AmBaSar- 
Phage-RGD was prepared using a method developed 
in  our  laboratory  with  minor  modifications[32]: 
[64Cu]Acetate (64Cu(OAc)2) was prepared by adding 
37-111  MBq  of  64CuCl2  into  pH  5.0~5.5  ammonium 
acetate buffer (0.1 N, 300 µL). The DOTA-phage-RGD 
or AmBaSar-Phage-RGD was then added to the above 
64Cu(OAc)2  solution,  and  the  resulting  mixture  was 
incubated at 23~37 °C for 30 min, followed by purifi-
cation with PD-10 column. The radioactive peak con-
taining  64Cu-DOTA-Phage-RGD  or 
64Cu-AmBaSar-Phage-RGD was collected for the fu-
ture use. 
In vitro assay 
 Purified T7 and T7-RGD phages were fluores-
cently labeled and used for the affinity detection with 
integrin  αvß3 in  a  standard  ELISA  assay.  The  wells 
were first coated with different concentration of αvß3, 
and then washed, blocked with 5% milk and coated 
with different amount of Alexa Fluor-488 (Invitrogen) 
labeled T7-RGD phage or wild type T7 phage. After 
washed,  the  fluorescence  intensity  was  measured 
under appropriate excitation and emission setting. To 
test whether the RGD displayed on T7 phage surface 
can interact or mediate the internalization of phage 
through  the  interaction  with  integrin  expressed  on 
cancer  cell  surfaces,  both  prefixed  (cells  were  fixed 
first then incubated with phage) and living ovarian 
cancer cells (cells were incubated with phage first then 
detached  and  fixed)  were  used.  When  SKOV3  or 
U87MG (high expression of integrin αvβ3)[33-35] grew 
to  70%  confluent,  they  were  detached  by  treatment 
with  trypsin  and  fixed  by  4%  glutaraldehyde,  then 
incubated with labeled T7 or T7-RGD phage. Alterna-
tively, labeled phages were directly added to the at-
tached  living  SKOV3  or  U87MG  cells  without  any 
fixation. After incubation for 1 h, cells were dissoci-
ated, washed, fixed, and observed under microscope.  
Animal Models 
 Athymic  nude  mice  (about  10–20  weeks  old, 
with a body weight of 20–25 g) were obtained from 
Harlan (Charles River, MA). All animal experiments 
were performed according to a protocol approved by 
University  of  Southern  California  Institutional  Ani-
mal  Care  and  Use  Committee.  The  U87MG  human 
glioma  xenograft  model  was  generated  by  subcuta-
neous injection of 5 × 106 U87MG human glioma cells 
into the front flank of athymic nude mice. The tumors 
were allowed to grow 3-5 weeks until 200-500 mm3 in 
volume.  Tumor  growth  was  followed  by  caliper 
measurements of the perpendicular dimensions.  
In Vivo Near-infrared optical imaging of tumors 
In  vivo  fluorescence  imaging  was  performed 
with  an  IVIS  200  small  animal  imaging  system 
(Xenogen, Alameda, CA). The system was equipped 
with 21 emmission filter sets that can be used to image 
optical signals from green to near-infrared. A Cy5.5 
filter set was used for acquiring the fluorescence of 
Cy5.5-Phage-RGD in vivo. Identical illumination set-
tings  (lamp  voltage,  filters,  f/stop,  field  of  views, 
binning) were used for acquiring all images. Fluores-
cence emission was normalized to photons per second 
per  centimeter  squared  per  steradian  (p/s/cm2/sr). 
Images  were  analyzed  using  Living  Image  4.0  soft-
ware  (Xenogen)  to  allow  the  spectral  unmixing,  re-
duce  the  tissue  autofluorescence  and  crosstalk.  The 
experimental  mice  (n=3)  were  injected  with  Cy5.5 
conjugated RGD-phages via the tail vein, anesthetized 
with 2% isoflurane, and followed with static scans. All 
near-infrared fluorescence images were acquired us-
ing  a  1-second  exposure  time  (f/stop=  4).  For  each 
imaging scan, regions of interest (ROIs) were drawn 
over each tumor xenograft site to semi-quantify the 
signals.  The  mice  were  euthanized  at  72  hours 
post-injection.  The  tumor  and  major  organs  were 
dissected,  and  ex vivo  fluorescence  images  were  ac-
quired to confirm the in vivo results. 
microPET Studies 
 Micro-PET scans were performed using a rodent 
scanner (microPET R4; Siemens Medical Solutions) as 
previously  reported  [36].  About  11.1  MBq  of 
64Cu-DOTA-Phage-RGD  or 
64Cu-AmBaSar-Phage-RGD  was  intravenously  in-
jected into each  mouse under isoflurane anesthesia. 
Ten minute static scans were acquired at desired time 
points.  The  images  were  reconstructed  by  a 
2-dimensional ordered-subsets expectation maximum 
(OSEM) algorithm. For each microPET scan, regions 
of interest were drawn over the tumor, normal tissue, 
and major organs on the decay-corrected whole-body 
coronal  images. The radioactivity concentration (ac-
cumulation)  within  the  tumor,  muscle,  liver,  and 
kidneys were obtained from the mean value within 
the multiple regions of interest and then converted to 
%ID/g.  For  the  RGD  blocking  experiment,  mice 
bearing U87MG tumors were scanned (10 min static) 
at desired time points after the coinjection of 11.1 MBq 
64Cu-AmBaSar-Phage-RGD with 30 mg/kg RGD per 
mouse.  For  phage-RGD  blocking,  100  times 
phage-RGD  was  injected  3  min  before  the  admin-
istration  of  11.1  MBq  64Cu-AmBaSar- 





 Quantitative data were expressed as mean ± SD. 
Means were compared using One-way ANOVA and 
student’s t-test. P values < 0.05 were considered sta-
tistically significant.  
RESULTS 
Chemistry and Radiochemistry  
 Wild type T7 bacteriophages were purified from 
clarified lysates by precipitation with 10% PEG 8000 
followed by banding in a CsCl step gradient. How-
ever, the yield of T7-RGD was found too low by using 
the  same  procedure.  Majority  of  T7-RGD  particles 
became  insoluble.  By  lowering  the  concentration  of 
PEG  from  10%  to  3%  with  the  addition  of 
2-mecapataethanol,  the  insolubility  of  T7-RGD  was 
greatly diminished and could be readily purified to a 
concentration as high as 1013 pfu/ml. After the con-
jugation to chelators, the labeling yield was 25±5% for 
DOTA-Phage-RGD  and  48±6%  for  Am-
BaSar-Phage-RGD. 
Cell Adhesion assay 
 The  interaction  between  T7-RGD  and  αvβ3 in-
tegrin is first demonstrated by ELISA experiment. As 
shown in Figure 2A, compared to unmodified wild 
type T7 phage, T7-RGD phage is able to bind to the 
coated integrin in a dose dependent manner. When 
fibronectin, a demonstrated binding ligand of integrin 
via  RGD  peptide,  was  introduced,  the  interaction 
between integrin and T7-RGD phage is largely inhib-
ited (data not shown), indicating the interaction be-
tween the phage and integrin is indeed mediated by 
RGD peptide displayed on the phage surface. To test 
whether the RGD displayed on T7-RGD phage surface 
can interact or mediate the internalization of phage 
through the binding with integrin expressed on can-
cer cell surfaces, both prefixed and living SKOV3 cells 
were used.  
 
 
FIGURE  2.  (A)  Binding 
between  T7-RGD  phage 
and  integrin  αvβ3.  (B) 
Confocal  microscopic 
images  of  fixed  SKOV3 
ovarian cancer cells labeled 
with  488  conjugated  wild 
type T7 (left, the exposure 
of control sample was further 
extended to study the weak 
binding with wild type phage) 
and T7-RGD (right) phage. 
(C) TEM images of DOTA 
and  AmBaSar  cage  modi-
fied phage particles.  
 
 




As shown in Figure 2B, when cells were fixed, 
the  T7-RGD  phage  was  found  only  binding  to  cell 
membrane where integrins were located. In contrast, 
almost  no  fixed  cells  were  labeled  by  wild-type  T7 
phage. When living cells were used, about 80% cells 
were either weakly or strongly labeled by T7-RGD, 
while only 10-20% SKOV3 cells were labeled by T7. 
Furthermore,  the  localization  of  T7-RGD  phage 
seemed to be both cytoplasm and membrane-bound, 
whereas  T7  was  only  found  intracellular  (Supple-
mentary  Material:  Figure  S1).  The  U87MG  cell  be-
haves  similarly  and  the  T7-RGD  demonstrated  ~  4 
fold higher uptake compared with wild type T7 phage 
in living cells. These results clearly demonstrated that 
the RGD displayed on T7-RGD phage surface could 
mediate the internalization of phage through the in-
teraction with integrin expressed on cancer cell sur-
faces.  
In vivo Imaging of U87MG Tumor-Bearing Mice  
 As shown in Figure 2C, the morphology of the 
phage was unchanged after the modification based on 
the  TEM  images.  After  the  phage  was  radiolabeled 
with 64Cu (25±5% labeling yield), whole body imaging 
experiments were performed (Figure 3). The U87MG 
tumor (integrin αvβ3 positive) could be clearly visual-
ized  in  microPET  images  and  the  tumor  uptake 
reached a plateau after 4 h post injection (~9%ID/g). 
When  Cy5.5-Phage-RGD  was  imaging  using  optical 
machine, much prominent tumor uptake and lower 
liver  uptake  was  obtained  (Fig.  3C).  In  addition  to 
DOTA-phage-RGD  particle,  we  introduced  the  sar-
cophagine (Sar) cage to the surface of the phage par-
ticle according to our previous procedure. Based on 
the TEM images, the morphology of phage was not 
changed after the modification with Sar cage (Figure 
2C). After  64Cu radiolabeling (45±7% labeling yield), 
microPET imaging was performed in U87MG tumor 
model.  At  1  h  time  point,  64Cu-DOTA-phage-RGD 
and  64Cu-AmBaSar-Phage-RGD  have  comparable 
tumor  uptake  (Figure  4,  7.9±2.3%ID/g  and 
8.8±0.7%ID/g,  respectively).  However, 
64Cu-AmBaSar-Phage-RGD  showed  high  tumor  up-
take  at  late  time  points  (13.4±0.5,  14.3±0.9,  and 
13.2±1.5%ID/g,  at  4,  16,  and  24  h,  respectively). 
64Cu-AmBaSar-Phage-RGD also demonstrated signif-
icantly  lower  liver  uptake  (51.2±4.1,  44.9±3.4,  and 
32.3±2.6%ID/g  for  64Cu-DOTA-phage-RGD;  com-
pared  with  34.1±4.9,  25.6±2.3,  and  20.7±2.2%ID/g 
64Cu-AmBaSar-Phage-RGD at 1, 4, and 16 h, respec-
tively), which could be attributed to the stability dif-
ference between two chelators. There is no significant 
difference between two tracers regarding the uptake 
in kidney and muscle at all time points tested (Sup-
plementary Material: Figure S2).  
 
FIGURE  3.  (A)  Coronal  microPET  images  of  nude  mouse  bearing  U87MG  tumor  at  1  h,  4  h,  and  16  h  p.i.  of 
64Cu-DOTA-Phage-RGD. (B) Time activity curve derived from multi-time point microPET study (n=3). (C) Optical images of 





FIGURE  4.  Coronal  microPET  images  of  nude  mouse  bearing  U87MG  tumor  at  1  h,  4  h,  16  h,  and  24  h  p.i.  of 
64Cu-AmBaSar-Phage-RGD. (B) Time activity curve derived from multi-time point microPET study (n=3). 
 
FIGURE 5. (A) Coronal microPET images of U87MG tumor bearing nude mice after injection of 64Cu-AmBaSar-Phage-RGD with 
a blocking dose Phage-RGD. (B) The unlocked/ blocked tumor and major organ uptake derived from microPET study (n=3). 
 
In  order  to  confirm  the  receptor  specificity, 
blocking  experiment  was  performed.  In  the  RGD 
blocking experiment, cold RGD peptide was injected 2 
min  before  the  administration  of  64Cu-AmBaSar- 
T7-RGD. Tumor uptake was partially blocked at 1h 
time point and the blocking became less effective at 
late time points (Supplementary Material: Figure S3). 
The tracer uptake in other major organs has no sig-
nificant  difference  between  blocked  and  unblocked 
mice. We also performed the blocking experiment by 
using phage particle as the competitive ligand (Figure 




reduced and the value was kept at low level consist-
ently. The more effective blocking may be attributed 
to  the  matched  half-life  between  phage  and 
64Cu-AmBaSar-phage. Nonetheless, a more systematic 
study would be needed before a conclusion is drawn. 
The tracer uptake in other major organs has no sig-
nificant  difference  between  the  blocked  and  un-
blocked mice. 
DISCUSSION 
 Phage  display  technology  is  emerging  as  a 
powerful approach to develop novel peptide ligands 
for  a  specific  molecular  target  [13].  However,  the 
screening process could be time consuming and the 
success  is  not  guaranteed.  Although  target  specific 
radiolabeled  phage  particles  obtained  from  either 
high  throughput  screen  (phage  display)  or  rational 
design (the expression of established affinity reagents 
on the phage surface) have been reported in molecular 
imaging of variety of diseases, most of the imaging 
results are still suboptimal [18, 19]. In this report, we 
demonstrated that  the  phage based organic particle 
could be used as an imaging agent.  
By using standard molecular cloning technique, 
a DNA fragment which encodes CRGDFKC peptide 
sequence  was  introduced  into  T7  genome.  The  re-
sulting recombinant T7 phage (T7-RGD) enabled the 
expression  and  display  of  415  copies  of 
RGD-containing  peptides  on phage surface. The in-
troduction of two cysteins at both ends might facili-
tate  the  formation  of  cyclic  structure,  which  could 
possibly  lead  to  stronger  binding  to  integrins.  The 
T7-RGD  particles  can  be  readily  purified  under  re-
ducing environment to a concentration as high as 1 × 
1013 pfu/ml.  
After confirming the receptor binding in vitro, we 
then evaluated the T7-RGD phage as PET agent for 
cancer imaging. Copper-64 (t1/2 = 12.7 h) decays by β+ 
(20%) and β- emission (37%), as well as electron cap-
ture  (43%),  making  it  well  suited  for  radiolabeling 
proteins, antibodies and peptides, both for PET im-
aging (β+) and therapy (β+ and β-) [24, 37]. In vivo sta-
ble  attachment  of  64Cu2+  to  targeted  biomolecules 
generally requires the use of a bifunctional chelator 
(BFC). In order to label our integrin targeted phage 
particle,  1,4,7,10-tetraazadodecane-N,N',N",N"'- 
tetraacetic acid (DOTA) was conjugated to the parti-
cle. Although we have obtained promising imaging 
result for DOTA-phage-RGD particle, the liver uptake 
of this tracer was rather high with ~50%ID/g at 1h 
and  ~30%ID/g  at  16h.  It  is  well  known  that  the 
DOTA, TETA, and their derivatives, for  64Cu2+ label-
ing have limited stability in vivo due to the dissocia-
tion of 64Cu2+ from these BFCs, leading to high reten-
tion in liver. Recently, we have developed a carbox-
ylate functionalized sarcophagine chelator AmBaSar 
for  64Cu2+  radiolabeling,  which  shows  improved 
pharmacokinetics and dynamics due to the increased 
stability  [32,  38,  39].  We  then  introduced  the  sar-
cophagine cage to the surface of the phage particle 
according  to  our  previous  procedure. 
64Cu-AmBaSar-Phage-RGD  showed  high  tumor  up-
take  at  late  time  points.  64Cu-AmBaSar-Phage-RGD 
also  demonstrated  significantly  lower  liver  uptake, 
which could be attributed to the stability difference 
between two chelators. This information is important 
for  nanoparticle  based  imaging  studies.  It  clearly 
demonstrated that the choice of chelator could have 
significant impact on imaging results. As the imaging 
tags were an insignificant component compared to the 
whole T7 phage, the distribution pattern of T7-RGD 
phage should be mainly determined by the particle 
itself. However, the 64Cu-DOTA-Phage-RGD demon-
strated more than 50% higher liver uptake compared 
with  64Cu-AmBaSar-Phage-RGD.  The  difference  in 
these nanoparticle based PET agents could be mainly 
caused  by  the  release  of  free  Cu  when  an  unstable 
chelator was selected. In fact, when Cy5.5 was tagged 
to the Phage-RGD particle (Fig. 3C), the particle dis-
tribution  pattern  correlates  well  with 
64Cu-AmBaSar-Phage-RGD.  Therefore,  when  high 
liver uptake was observed for  64Cu labeled nanopar-
ticle agents, it could not only be caused by the reticu-
loendothelial clearance, but also by the free  64Cu fell 
off from the particle.  
Unlike peptide based imaging agent, the reten-
tion time of phage particle was shown to be high and 
persistent in tumors. Due to its large size (~50 nm), 
high liver uptake was observed at early time point, 
and  the  value  keep  decreasing  at  late  time  points. 
These characters make the phage particles more suit-
able to be used as theranostic agent instead of pure 
imaging  agent.  Although  these  newly  developed 
phage  agents  were  only  labeled  with  64Cu  for  PET 
imaging in this application, the same construct may 
also  be  labeled  with  therapeutics  isotopes  (such  as 
67Cu/90Y) for targeted radio-immunotherapy of can-
cer. Moreover, for future phage based therapy appli-
cations  (including  radio,  chemo  and/or  gene  thera-
py),  optimization  of  this  newly  developed  phage 
platform could be performed through molecular im-
aging (using PET to select the best carrier with opti-
mal tumor up-take and in vivo distribution) before the 
lengthy and costly therapy experiments. In summary, 
a  PET  trackable  imaging  platform  was  developed 
based  on  phage  particle,  which  are  physically  well 
characterized,  trackable  after  surface  modification, 





While  theranostic  approach  has  become  an  at-
tractive strategy for in vivo cancer imaging and ther-
apy studies, there is a significant shortage of estab-
lished  platforms/methods  for  biodegradable 
theranostic agent construction. In this report, we con-
structed  a  PET  trackable  nanoplatform  based  on 
phage particle and demonstrated the imaging capa-
bility of these targeted agents. We also demonstrated 
that the choice of chelator could have significant im-
pact on imaging results. Moreover, these newly de-
veloped agents hold great therapeutic potential due to 
their high loading capacity and superior targeted de-
livery  ability,  which  could  turn  them  into  novel 
theranostic  agents.  The  method  established  in  this 
research  should  be  applicable  to  other  recep-
tor/ligand systems for theranostic agent construction, 
which could have an immediate and profound impact 
on the field of imaging/therapy and lay the founda-
tion  for  the  construction  of  next  generation  cancer 
specific theranostic agents.  
SUPPLEMENTARY MATERIAL 
Figs. S1 - S3.  http://www.thno.org/v01p0371s1.pdf 
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